As the demand for GLP-1 medications like Ozempic grows, many Americans are turning to unregulated online sellers to access these drugs. This shift is often driven by high costs, insurance issues, and ongoing shortages at local pharmacies.
The U.S. Food and Drug Administration (FDA) has issued warnings about these “gray-market” GLP-1 drugs, which include semaglutide and tirzepatide. The FDA states that these drugs are not evaluated for safety, quality, or effectiveness. Because they are not part of the approved drug supply, they may be counterfeit or contaminated, posing serious health risks.
Many of these unregulated products are marketed online as “compounded semaglutide” or labeled for “research use only.” Recent studies indicate that some of these products might contain forms of semaglutide that are not recognized by the FDA.
Experts express concern that the rise of gray-market GLP-1 medications could damage public trust in the healthcare system and complicate drug safety monitoring worldwide. Dr. Frank Dumont, a medical director at Virta Health in Colorado, pointed out that the increase in these unregulated products reflects a high demand for medications that many see as vital for managing weight and diabetes.
Gray-market medications bypass the usual safety protocols, increasing the risks for users. Dr. Dumont emphasized that prescription drugs need strict regulation to ensure safety, and bypassing these processes can lead to unknown outcomes and medical risks.
The easy access to online vendors has made it simple for consumers to encounter dubious sources when searching for GLP-1 medications. Many of these individuals are seeking more affordable options, especially since the FDA-approved versions can cost over $1,000 a month without insurance.
Additionally, misinformation about DIY or compounded medications fuels the problem, making it hard for buyers to distinguish legitimate products from scams. Dr. Dumont cautions that vague promises about these drugs often lack accountability.
Recently, the FDA confirmed incidents of counterfeit Ozempic units being sold within the U.S., which raised alarm and led to investigations. Reports of serious health issues linked to these unregulated drugs, including overdosing and severe side effects, have prompted federal and state regulators to increase enforcement. Attorneys general from 38 states have called for stricter measures against counterfeit distributors.
Consumers are advised to avoid unregulated products and stick with FDA-approved medications. Dr. Dumont’s recommendation is straightforward: when it comes to online purchases, be wary. If something seems too good to be true, it probably is.
